All In Biotech

NDA 211723 · Epizyme INC

Tazverik

Tazemetostat Hydrobromide · Oral

NovelAccelerated approvalPriority reviewOrphanDiscontinued

Last checked: Nov 20, 2026Latest source record: Aug 13, 2024 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2020

Jan 23, 2020

Approved uses

1

Original approval plus efficacy supplements

Registered trials

3

0 Phase 3, 0 recruiting

FAERS reports

1,622

721 serious, 216 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Apr 29, 2026.

TAZVERIK is a methyltransferase inhibitor indicated for the treatment of: Adults and pediatric patients aged 16 years and older with metastatic or locally advanced epithelioid sarcoma not eligible for complete resection. ( 1.1 ) Adult patients with relapsed or refractory follicular lymphoma whose tumors are positive for an EZH2 mutation as detected by an FDA-approved test and who have received at least 2 prior systemic therapies. ( 1.2 ) Adult patients with relapsed or refractory follicular lymphoma who have no satisfactory alternative treatment options. ( 1.2 ) These indications are approved under accelerated approval based on overall response rate and duration of response. Continued approval for these indications may be contingent upon verification and description of clinical benefit in a confirmatory trial(s). 1.1 Epithelioid Sarcoma TAZVERIK is indicated for the treatment of adults and pediatric patients aged 16 years and older with metastatic or locally advanced epithelioid sarcoma not eligible for complete resection. This indication is approved under accelerated approval based on overall response rate and duration of response [see Clinical Studies ( 14.1 )]. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s). 1.2 Relapsed or Refractory Follicular Lymphoma TAZVERIK is indicated for the treatment of adult patients with relapsed or refractory (R/R) follicular lymphoma (FL) whose tumors are positive for an EZH2 mutation as detected by an FDA-approved test and who have received at least 2 prior systemic therapies. TAZVERIK is indicated for the treatment of adult patients with R/R FL who have no satisfactory alternative treatment options. These indications are approved under...

Mechanism: Tazemetostat is an inhibitor of the methyltransferase, EZH2, and some EZH2 gain-of-function mutations including Y646X, A682G, and A692V. Tazemetostat also inhibited EZH1 with a half-maximal inhibitory concentration (IC 50 ) of 392 nM, approximately 36 times higher than the IC 50 for inhibition of EZH2. The most well-characterized function of EZH2 is as the catalytic subunit of the polycomb repressive complex 2 (PRC2), catalyzing mono-, di-, and trimethylation of lysine 27 of histone H3. Trimethylation of histone H3 leads to transcriptional repression. SWItch/Sucrose Non-Fermentable (SWI/SNF)...

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Jan 23, 2020 Original approval · Type 1 - New Molecular Entity · priority review NovelAccelerated approvalOrphanLetterLabelReview
1 products under this application
  • TAZVERIK · TAZEMETOSTAT HYDROBROMIDE EQ 200MG BASE · TABLET, ORAL · Discontinued

Clinical trials

Interventional ClinicalTrials.gov studies with "Tazemetostat Hydrobromide" as an intervention, any sponsor and status, largest first.

All 3 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • off label use335
  • fatigue326
  • disease progression305
  • nausea235
  • product dose omission issue212
  • death132
  • diarrhoea123
  • decreased appetite97
  • vomiting95
  • asthenia83
  • constipation80
  • headache74

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20173
201811
20196
202081
2021256
2022395
2023316
2024205
2025242
2026107

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

  • To Be Discontinued · updated Mar 27, 2026

    Tazverik, Tablet, 200 mg (NDC 72607-100-00). Discontinuation of the manufacture of the drug product

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Tazverik (Tazemetostat Hydrobromide)

2024 spending

$25.1M

Beneficiaries

228

1,417 claims

Per beneficiary

$110,237

$81.67 per unit

View as table
YearSpending
2020$2,816,560
2021$8,150,727
2022$14,801,232
2023$18,985,929
2024$25,134,062

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 1 on PubMed

Sponsor: Epizyme INC

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.